Prospects for flavonoid and related phytochemicals as nature-inspired treatments for Clostridium difficile infection

Journal of Applied Microbiology

Volumn 116, Issue 1, 2014, Pages 23-31

  Wu, X ^a   Alam, M Z ^a   Feng, L ^b   Tsutsumi, L S ^b   Sun, D ^b   Hurdle, J G ^a  

^a UNIVERSITY OF TEXAS AT ARLINGTON   (United States)

^b UNIVERSITY OF HAWAII AT HILO   (United States)

Author keywords

Antibiotics; Antimicrobials; Intestinal microbiology; Mechanism of action

Indexed keywords

BIOELECTRIC POTENTIALS; CLOSTRIDIUM;

ANTIBACTERIALS; ANTIMICROBIAL; CLOSTRIDIUM DIFFICILE; FLAVONOID; INTESTINAL MICROBIOLOGY; MECHANISM OF ACTION; NATURALLY OCCURRING; PHYTOCHEMICAL; POLYPHENOLS; PROPERTY;

FLAVONOIDS;

2' HYDROXYFLAVANONE; 2' METHOXYFLAVONE; 3 HYDROXYFLAVONE; 3,7 DIHYDROXYFLAVONE HYDRATE; 6 AMINOFLAVONE; 6 HYDROXYFLAVANONE; 6 HYDROXYFLAVONE; 6 METHOXYFLAVONE; 7 AMINOFLAVONE; 7 HYDROXYFLAVONE; ALPHA NAPHTHOFLAVONE; ANTIBIOTIC AGENT; BETA NAPHTHOFLAVONE; BIOCHANIN A; CHRYSIN; FLAVONOID; HESPERETIN; KAEMPFEROL; METRONIDAZOLE; NARINGENIN; OLYMPICIN A; PRIMULETIN; QUERCETIN; TAXIFOLIN; UNCLASSIFIED DRUG; VANCOMYCIN; ANTIINFECTIVE AGENT; BACTERIAL TOXIN; PLANT MEDICINAL PRODUCT;

ANTIMICROBIAL ACTIVITY; DISEASE TREATMENT; INFECTIOUS DISEASE; MEDICINE; OPTIMIZATION; PHYTOCHEMISTRY; PLANT COMMUNITY; SPORULATION;

ANTIBACTERIAL ACTIVITY; ARTICLE; BACTERIAL GROWTH; BACTERIAL STRAIN; CELL DEATH; CLOSTRIDIUM DIFFICILE INFECTION; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; MEMBRANE POTENTIAL; MINIMUM BACTERICIDAL CONCENTRATION; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PHARMACOPHORE; TIME; TRADITIONAL MEDICINE; CHEMISTRY; CLOSTRIDIUM INFECTION; PEPTOCLOSTRIDIUM DIFFICILE;

BACTERIA (MICROORGANISMS); CLOSTRIDIUM DIFFICILE;

ANTI-BACTERIAL AGENTS; BACTERIAL TOXINS; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM INFECTIONS; FLAVONOIDS; PHYTOCHEMICALS;

EID: 84890429883     PISSN: 13645072     EISSN: 13652672     Source Type: Journal    
DOI: 10.1111/jam.12344     Document Type: Article

References (30)

1. Balakrishnan, M. and Floch, M.H. (2012) Prebiotics, probiotics and digestive health. Curr Opin Clin Nutr Metab Care 15, 580-585.
2. Barbosa, E., Calzada, F. and Campos, R. (2007) In vivo antigiardial activity of three flavonoids isolated of some medicinal plants used in Mexican traditional medicine for the treatment of diarrhea. J Ethnopharmacol 109, 552-554.
3. Bartlett, J.G. and Gerding, D.N. (2008) Clinical recognition and diagnosis of Clostridium difficile infection. Clin Infect Dis 46(Suppl 1), S12-S18.
4. Brazier, J.S. (2008) Clostridium difficile: from obscurity to superbug. Br J Biomed Sci 65, 39-44.
5. Cushnie, T.P. and Lamb, A.J. (2011) Recent advances in understanding the antibacterial properties of flavonoids. Int J Antimicrob Agents 38, 99-107.
6. Freeman, J., Bauer, M.P., Baines, S.D., Corver, J., Fawley, W.N., Goorhuis, B., Kuijper, E.J. and Wilcox, M.H. (2010) The changing epidemiology of Clostridium difficile infections. Clin Microbiol Rev 23, 529-549.
7. Gerding, D.N., Muto, C.A. and Owens, R.C. Jr (2008) Treatment of Clostridium difficile infection. Clin Infect Dis 46(Suppl 1), S32-S42.
8. Havsteen, B. (1983) Flavonoids, a class of natural products of high pharmacological potency. Biochem Pharmacol 32, 1141-1148.
9. He, M., Miyajima, F., Roberts, P., Ellison, L., Pickard, D.J., Martin, M.J., Connor, T.R., Harris, S.R. et al. (2013) Emergence and global spread of epidemic healthcare-associated Clostridium difficile. Nat Genet 45, 109-113.
10. Hurdle, J.G., Heathcott, A., Yang, L., Yan, B. and Lee, R.E. (2011a) Reutericyclin and related analogues kill stationary phase Clostridium difficile at achievable colonic concentrations. J Antimicrob Chemother 66, 1773-1776.
11. Hurdle, J.G., O'Neill, A.J., Chopra, I. and Lee, R.E. (2011b) Targeting bacterial membrane function: an underexploited mechanism for treating persistent infections. Nat Rev Microbiol 9, 62-75.
12. Kamiya, S., Ogura, H., Meng, X.Q. and Nakamura, S. (1992) Correlation between cytotoxin production and sporulation in Clostridium difficile. J Med Microbiol 37, 206-210.
13. Kaneda, T. (1991) Iso- and anteiso-fatty acids in bacteria: biosynthesis, function, and taxonomic significance. Microbiol Rev 55, 288-302.
14. Lee, H.C., Jenner, A.M., Low, C.S. and Lee, Y.K. (2006) Effect of tea phenolics and their aromatic fecal bacterial metabolites on intestinal microbiota. Res Microbiol 157, 876-884.
15. Lewis, K. and Ausubel, F.M. (2006) Prospects for plant-derived antibacterials. Nat Biotechnol 24, 1504-1507.
16. Loa, J., Chow, P. and Zhang, K. (2009) Studies of structure-activity relationship on plant polyphenol-induced suppression of human liver cancer cells. Cancer Chemother Pharmacol 63, 1007-1016.
17. Louie, T.J., Miller, M.A., Mullane, K.M., Weiss, K., Lentnek, A., Golan, Y., Gorbach, S., Sears, P. et al. (2011) Fidaxomicin versus vancomycin for Clostridium difficile infection. N Engl J Med 364, 422-431.
18. Merrigan, M., Venugopal, A., Mallozzi, M., Roxas, B., Viswanathan, V.K., Johnson, S., Gerding, D.N. and Vedantam, G. (2010) Human hypervirulent Clostridium difficile strains exhibit increased sporulation as well as robust toxin production. J Bacteriol 192, 4904-4911.
19. Musher, D.M., Aslam, S., Logan, N., Nallacheru, S., Bhaila, I., Borchert, F. and Hamill, R.J. (2005) Relatively poor outcome after treatment of Clostridium difficile colitis with metronidazole. Clin Infect Dis 40, 1586-1590.
20. Novo, D., Perlmutter, N.G., Hunt, R.H. and Shapiro, H.M. (1999) Accurate flow cytometric membrane potential measurement in bacteria using diethyloxacarbocyanine and a ratiometric technique. Cytometry 35, 55-63.
21. Orenstein, R. (2012) Fidaxomicin failures in recurrent Clostridium difficile infection A problem of timing. Clin Infect Dis 55, 613-614.
22. Pepin, J., Alary, M.E., Valiquette, L., Raiche, E., Ruel, J., Fulop, K., Godin, D. and Bourassa, C. (2005) Increasing risk of relapse after treatment of Clostridium difficile colitis in Quebec, Canada. Clin Infect Dis 40, 1591-1597.
23. Pepin, J., Valiquette, L., Gagnon, S., Routhier, S. and Brazeau, I. (2007) Outcomes of Clostridium difficile-associated disease treated with metronidazole or vancomycin before and after the emergence of NAP1/027. Am J Gastroenterol 102, 2781-2788.
24. Rupnik, M., Wilcox, M.H. and Gerding, D.N. (2009) Clostridium difficile infection: new developments in epidemiology and pathogenesis. Nat Rev Microbiol 7, 526-536.
25. Shiu, W.K., Rahman, M.M., Curry, J., Stapleton, P., Zloh, M., Malkinson, J.P. and Gibbons, S. (2012) Antibacterial acylphloroglucinols from Hypericum olympicum. J Nat Prod 75, 336-343.
26. Stevenson, D.E. and Hurst, R.D. (2007) Polyphenolic phytochemicals-just antioxidants or much more? Cell Mol Life Sci 64, 2900-2916.
27. Sun, D., Hurdle, J.G., Lee, R., Cushman, M. and Pezzuto, J.M. (2012) Evaluation of flavonoid and resveratrol chemical libraries reveals abyssinone II as a promising antibacterial lead. ChemMedChem 7, 1541-1545.
28. Warny, M., Pepin, J., Fang, A., Killgore, G., Thompson, A., Brazier, J., Frost, E. and McDonald, L.C. (2005) Toxin production by an emerging strain of Clostridium difficile associated with outbreaks of severe disease in North America and Europe. Lancet 366, 1079-1084.
29. Wu, J., Li, J., Cai, Y., Pan, Y., Ye, F., Zhang, Y., Zhao, Y., Yang, S. et al. (2011) Evaluation and discovery of novel synthetic chalcone derivatives as anti-inflammatory agents. J Med Chem 54, 8110-8123.
30. Wu, X., Cherian, P.T., Lee, R.E. and Hurdle, J.G. (2013) The membrane as a target for controlling hypervirulent Clostridium difficile infections. J Antimicrob Chemother 68, 806-815.